Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

94.52 -0.51 (-0.54%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	503,599
Open	94.73
Bid (Size)	94.02 (200)
Ask (Size)	96.40 (100)
Prev. Close	95.03
Today's Range	94.02 - 95.14
52wk Range	81.20 - 129.27
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Moderna (MRNA) Deep-Dive: Navigating the 7.5% Year-End Slide and the Path to a 2028 Recovery

December 24, 2025

As of December 24, 2025, Moderna, Inc. (Nasdaq: MRNA) finds itself at a pivotal crossroads in its corporate evolution. Once the definitive success story of the pandemic era, the Cambridge-based...

Via PredictStreet

The Pfizer Pivot: A Deep-Dive into PFE’s 2025 Financial Recovery and Strategic Rebirth

December 22, 2025

As of today, December 22, 2025, Pfizer Inc. (NYSE: PFE) stands as a case study in corporate reinvention and the brutal reality of the post-pandemic "hangover." Once the darling of the global healthcare...

Via PredictStreet

Performance

YTD	-18.0%	-18.0%
1 Month	-8.4%	-8.4%
3 Month	-3.6%	-3.6%
6 Month	-11.2%	-11.2%
1 Year	-17.1%	-17.1%

More News

Earnings Scheduled For November 3, 2025 ↗

November 03, 2025

Via Benzinga

Moderna (MRNA): The “Act 2” of an mRNA Pioneer – A 2025 Deep Dive

December 22, 2025

Via PredictStreet

BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field

December 18, 2025

From BioNTech SE

Via GlobeNewswire

Pfizer's Muted 2026 Outlook Sends Ripples Through Pharmaceutical Sector

December 16, 2025

Via MarketMinute

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer

December 09, 2025

From BioNTech SE

Via GlobeNewswire

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer

December 06, 2025

From BioNTech SE

Via GlobeNewswire

BioNTech Achieves Minimum Condition in CureVac Exchange Offer

December 03, 2025

From BioNTech SE

Via GlobeNewswire

Moderna, BioNTech Slammed After FDA Links Covid Shots To 10 Deaths ↗

December 01, 2025

Via Investor's Business Daily

2 Top Dividend Stocks to Buy and Hold ↗

November 30, 2025

Via The Motley Fool

BioNTech (BNTX) Q3 2025 Earnings Call Transcript ↗

November 27, 2025

Via The Motley Fool

BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration

November 26, 2025

From BioNTech SE

Via GlobeNewswire

Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run ↗

November 13, 2025

Via Benzinga

BioNTech Says Collaboration With Pfizer Going Strong After Report Indicated US Pharma Giant Considering Stake Sale In The German Company ↗

November 13, 2025

Via Stocktwits

BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership ↗

November 03, 2025

Via Benzinga

BioNTech SE (NASDAQ:BNTX) Reports Mixed Q3 2025 Results with Major Revenue Beat and Quarterly Loss ↗

November 03, 2025

Via Chartmill

BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update

November 03, 2025

From BioNTech SE

Via GlobeNewswire

BioNTech to Host Innovation Series R&D Day on November 11, 2025

October 28, 2025

From BioNTech SE

Via GlobeNewswire

Healthcare Sector Navigates Volatile Waters as S&P 500 Closes: A Deep Dive into Key Market Drivers

October 27, 2025

Via MarketMinute

BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025

October 27, 2025

From BioNTech SE

Via GlobeNewswire

2 Unstoppable Dividend Stocks Yielding More Than 4% That Income-Seeking Investors Will Want to Buy in November and Hold Forever ↗

October 25, 2025

Via The Motley Fool

BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.

October 22, 2025

From BioNTech SE

Via GlobeNewswire

Beyond The Numbers: 7 Analysts Discuss BioNTech Stock ↗

October 10, 2025

Via Benzinga

Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook

October 08, 2025

Via MarketMinute

Frequently Asked Questions

Is BioNTech SE - American Depositary Shares publicly traded?

Yes, BioNTech SE - American Depositary Shares is publicly traded.

What exchange does BioNTech SE - American Depositary Shares trade on?

BioNTech SE - American Depositary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for BioNTech SE - American Depositary Shares?

The ticker symbol for BioNTech SE - American Depositary Shares is BNTX on the Nasdaq Stock Market

What is the current price of BioNTech SE - American Depositary Shares?

The current price of BioNTech SE - American Depositary Shares is 94.52

When was BioNTech SE - American Depositary Shares last traded?

The last trade of BioNTech SE - American Depositary Shares was at 12/26/25 04:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.